Target Prescribers Sample Clauses
The "Target Prescribers" clause defines the specific group of healthcare professionals to whom a product, service, or promotional activity is directed. In practice, this clause typically outlines criteria such as medical specialty, geographic location, or prescribing authority, ensuring that marketing or educational efforts are focused on the most relevant prescribers. By clearly identifying the intended audience, the clause helps ensure compliance with regulatory requirements and maximizes the effectiveness of outreach efforts.
Target Prescribers. The Marketing Committee shall also set the recommended list pricing for Collaboration Products in the Territory and shall establish guidelines for any discount, rebate, price reduction or chargeback programs or policies applicable to Commercialization of Collaboration Products in the Territory.
Target Prescribers. The Target Prescribers of the Product shall be reasonably determined by Sanofi following good faith consultations with Regulus.
Target Prescribers. For each Calendar Year, Saturn shall review with the Marketing Committee by October 1 of the immediately preceding Calendar Year the specific Target Prescribers for the Product and the planned copromotion coverage by Saturn and Indevus, provided, however, that (i) the Target Prescribers for the Indevus Dedicated Sales Force shall be the Indevus Target Prescribers; and (ii) Saturn may also conduct Details to the Indevus Target Prescribers.
Target Prescribers. For each Calendar Year, the Marketing Committee shall determine by October 1 of the immediately preceding Calendar Year (using Commercially Reasonable Efforts to secure information prior to the anticipated Launch Date for the Launch Period) the specific Target Prescribers for Product and the allocation between Indevus and Odyssey of such Target Prescribers; provided, however, that the Target Prescribers for the Indevus Dedicated Sales Force shall be the High Potential Target Prescribers.
Target Prescribers. The Target Prescribers of the Co-Detail Product shall be reasonably determined by Infinity following good faith consultations with Intellikine.
Target Prescribers. The Target Prescribers of the Product shall be reasonably determined by Merck following good faith consultations with Metabasis.